Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 3Phase 1/2 2

Status

Completed 60Terminated 8Unknown 5Withdrawn 3Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 157Neoplasms 115Colorectal Neoplasms 97Breast Neoplasms 90Pancreatic Neoplasms 81Leukemia, Myeloid, Acute 81Recurrence 78Neoplasm Metastasis 78Prostatic Neoplasms 73Melanoma 73Ovarian Neoplasms 72Multiple Myeloma 66Stomach Neoplasms 60Squamous Cell Carcinoma of Head and Neck 55Lung Neoplasms 55Triple Negative Breast Neoplasms 50Glioblastoma 48Lymphoma 47Endometrial Neoplasms 43Carcinoma, Hepatocellular 43Advanced Solid Tumor 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Non-Hodgkin 41Advanced Solid Tumors 37Uterine Cervical Neoplasms 35Small Cell Lung Carcinoma 35Carcinoma, Renal Cell 34Lymphoma, Large B-Cell, Diffuse 32Lymphoma, B-Cell 32Sarcoma 29

Interventions

pembrolizumab 1cabozantinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Gliosarcoma × Clear all
NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

University of Alabama at Birmingham

Phase 1/2 Recruiting
28 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
6 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡